

Biostatistics Statement

22/10/2020

To whom it may concern,

Title of study: A prospective single-blinded single-center randomized controlled trial of Prep Kit-C and Moviprep: Does underlying Inflammatory Bowel Disease impact tolerability and efficacy?

Chief Investigator: A/P Susan Connor

Inflammatory Bowel Disease Lead Consultant

Liverpool Hospital, Sydney, NSW, Australia

This is a letter to confirm that I have read the ethics application for this study, contributed to the statistical analysis and the writing of the manuscript. In my opinion the statistical methods and techniques are appropriate for this research.

Please contact me if you have any queries.

Kind Regards,

Dr Ken Koo

Gastroenterologist and Hepatologist

Liverpool Hospital, Sydney, NSW, Australia

Email: Kanjkhoo@gmail.com